Home > Products > Novel inhibitors
Cat. No. Product name CAS No.
DCC2002 Errα Degrader-1

Novel PROTAC Estrogen-related Receptor α (ERRα) Degrader

2306388-84-9
DCC2003 Erso-dfp

Novel Activator of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer

DCC2004 Erß Nir Probe P5

The first ERβ-targeted near-infrared (NIR) inherently fluorescent probe, showing the advantages of high ERβ selectivity, good optical properties, and excellent ERβ imaging capability in living cells

DCC2005 Ertapenem Disodium

Carbapenem antibiotic, inhibiting cross-linking of the peptidoglycan layer of bacterial cell walls by blocking penicillin-binding proteins (PBPs)

153832-38-3
DCC2006 Erthermac

Novel thermosensitive fluorescent dye, visualizing thermogenesis in stimulated single-cell brown adipocytes

DCC2007 Er-thermo-yellow

The First Fluorescent Probe for Targeted Visualization of Temperature at the Endoplasmic Reticulum #222222; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0.17px; text-align: start; text-in

1445108-32-6
DCC2008 Erw1041e

Novel potent inhibitor of recombinant human and mouse Transglutaminase enzyme activity, mainly TG2 and the close related enzyme TG1

DCC2009 Erythrocentaurin

Anti-HBV agent, showing activities on HepG 2.2.15 cell line in vitro

50276-98-7
DCC2010 Erythro-di-o-benzyl Droxidopa Hcl

Precursor of adrenaline, suppressing the locomotor stimulation by MAO inhibitor

73594-44-2
DCC2011 Erythromycin Ethylsuccinate

Broad-spectrum, topical macrolide antibiotic, diffusing through the bacterial cell membrane and reversibly binding to the 50S subunit of the bacterial ribosome

1264-62-6
DCC2012 escaline Hydrochloride

Serotonin 5-HT2A Agonist

3166-82-3
DCC2013 Est64454

Novel Highly Soluble σ1 Receptor Antagonist for Pain Management

DCC2014 Estetrol

Selective estrogen receptor modulator (SERM), exhibiting estrogen agonism in certain tissues and estrogen antagonism in others

15183-37-6
DCC2015 Cgs-27023a

Non-Peptidic, potent, and orally active stromelysin inhibitor, blocking cartilage degradation

161314-70-1
DCC2016 Etb067

H-89 analog as PKA and AKT1 inhibitor with specificity on no longer inhibiting CAMK2B and neither affecting viability of mice nor causing any detectable tissuedamage at the dose given

1000995-79-8
DCC2017 Etc-131

Novel inhibitor of PORCN, inhibiting ß-catenin reporter activity in a dose-dependent manner

DCC2018 Ethd-1

Cell-impermeant viability indicator, as high-affinity nucleic acid stain that is weakly fluorescent until bound to DNA and emits red fluorescence (excitation/emission maxima ~528/617).

61926-22-5
DCC2019 Etheofazine

Novel anticancer agent

85609-79-6
DCC2020 Ethyl 3-hydroxyhexanoate

Natural potent antiviral agent, significantly inhibiting coxsackievirus group B (CVB) replication both in vivo and in vitro

2305-25-1
DCC2021 Ethyl Lipotf

Novel selective FTO inhibitor

1808089-27-1
DCC2022 Ethylvanillin

TRPA1 channel agonist

121-32-4
DCC2023 Etifoxine

Activator of β2 and β3 subunit containing channels of the GABAA receptor complex, stimulating the production of GABA(A) active neurosteroids

21715-46-8
Page 1313 / Total 1557 FirstPrevNextLastGoto